AMEX:VNRX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. More Details


Snowflake Analysis

High growth potential with excellent balance sheet.

Share Price & News

How has VolitionRx's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: VNRX's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-1.3%

VNRX

1.1%

US Medical Equipment

1.0%

US Market


1 Year Return

-34.8%

VNRX

15.4%

US Medical Equipment

13.6%

US Market

Return vs Industry: VNRX underperformed the US Medical Equipment industry which returned 15.4% over the past year.

Return vs Market: VNRX underperformed the US Market which returned 13.6% over the past year.


Shareholder returns

VNRXIndustryMarket
7 Day-1.3%1.1%1.0%
30 Day-12.1%1.5%-0.4%
90 Day-15.0%12.0%8.9%
1 Year-34.8%-34.8%16.4%15.4%16.2%13.6%
3 Year4.4%4.4%73.3%68.8%40.2%30.8%
5 Year-35.9%-35.9%149.6%130.6%89.6%68.2%

Price Volatility Vs. Market

How volatile is VolitionRx's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is VolitionRx undervalued compared to its fair value and its price relative to the market?

7.77x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate VNRX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate VNRX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: VNRX is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: VNRX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate VNRX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: VNRX is overvalued based on its PB Ratio (7.8x) compared to the US Medical Equipment industry average (3.9x).


Next Steps

Future Growth

How is VolitionRx forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

70.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: VNRX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).

Earnings vs Market: VNRX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: VNRX's is expected to become profitable in the next 3 years.

Revenue vs Market: VNRX's revenue (78.3% per year) is forecast to grow faster than the US market (9.7% per year).

High Growth Revenue: VNRX's revenue (78.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if VNRX's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has VolitionRx performed over the past 5 years?

-14.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: VNRX is currently unprofitable.

Growing Profit Margin: VNRX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: VNRX is unprofitable, and losses have increased over the past 5 years at a rate of 14% per year.

Accelerating Growth: Unable to compare VNRX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VNRX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-0.2%).


Return on Equity

High ROE: VNRX has a negative Return on Equity (-99.88%), as it is currently unprofitable.


Next Steps

Financial Health

How is VolitionRx's financial position?


Financial Position Analysis

Short Term Liabilities: VNRX's short term assets ($22.4M) exceed its short term liabilities ($4.7M).

Long Term Liabilities: VNRX's short term assets ($22.4M) exceed its long term liabilities ($2.9M).


Debt to Equity History and Analysis

Debt Level: VNRX's debt to equity ratio (14%) is considered satisfactory.

Reducing Debt: VNRX's debt to equity ratio has increased from 0% to 14% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: VNRX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: VNRX has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 19% each year.


Next Steps

Dividend

What is VolitionRx current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate VNRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate VNRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if VNRX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VNRX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of VNRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.9yrs

Average management tenure


CEO

Cameron Reynolds (49 yo)

8.92yrs

Tenure

US$517,691

Compensation

Mr. Cameron Reynolds, MBA has been the President and Chief Executive Officer of VolitionRX Ltd since October 6, 2011. He founded VolitionRX in 2010. Mr. Reynolds has been the Chief Executive Officer and Pr ...


CEO Compensation Analysis

Compensation vs Market: Cameron's total compensation ($USD517.69K) is about average for companies of similar size in the US market ($USD595.72K).

Compensation vs Earnings: Cameron's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Martin Faulkes
Executive Chairman8.92yrsUS$298.83k4.03%
$ 5.8m
Cameron Reynolds
Founder8.92yrsUS$517.69k2.54%
$ 3.7m
David Vanston
CFO & Treasurer3.42yrsUS$316.79k0.0060%
$ 8.6k
Jacob Micallef
Chief Scientific Officer5.67yrsUS$298.83k0.27%
$ 382.3k
Jason Terrell
Chief Medical Officer & CEO of Volition Americano dataUS$436.14k0.12%
$ 169.3k
Scott Powell
Executive Vice President of Investor Relationsno datano data0.13%
$ 194.0k
Louise Batchelor Day
Chief Marketing & Communications Officer4.42yrsno datano data
Thomas Bygott
Sales & Marketing Directorno datano data0.023%
$ 32.9k
Nathan Dewsbury
Chief Commercial Officer of Volition Veterinary Diagnostics Development LLC0.67yrno datano data
Terry Kelly
Chief Scientific Officer of Volition America Inc0.67yrno datano data
Heather Wilson-Robles
Chief Medical Officer of Volition Veterinary Diagnostics Development LLC0.67yrno datano data
Rodney Rootsaert
Corporate Secretary8.92yrsUS$262.72k0.044%
$ 63.4k

3.9yrs

Average Tenure

50.5yo

Average Age

Experienced Management: VNRX's management team is considered experienced (3.9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Martin Faulkes
Executive Chairman8.92yrsUS$298.83k4.03%
$ 5.8m
Cameron Reynolds
Founder8.92yrsUS$517.69k2.54%
$ 3.7m
Hwee Hoon Lee
Secretary of Hypergenomics Pte Limited and Director of Hypergenomics Pte Limitedno dataUS$90.84kno data
Edward Futcher
Independent Non-Executive Director4.25yrsUS$72.86k0.058%
$ 84.0k
Guy Innes
Lead Independent Directorno dataUS$94.36k3.1%
$ 4.5m
Robert Weinzierl
Member of Scientific Advisory Board8.92yrsno datano data
Andreas Ladurner
Member of Scientific Advisory Board8.92yrsno data0.0040%
$ 5.8k
Alan Colman
Chairman of Scientific Advisory Board & Independent Non Executive Director8.92yrsUS$114.66k0.34%
$ 485.9k
Roland Andersson
Member of Scientific Advisory Board5.17yrsno datano data
Jorge Reis-Filho
Member of Scientific Advisory Board5.17yrsno datano data
Stefan Holdenrieder
Member of Scientific Advisory Boardno datano datano data
Lee-Jen Wei
Member of Scientific Advisory Board2.5yrsno datano data

8.9yrs

Average Tenure

64yo

Average Age

Experienced Board: VNRX's board of directors are considered experienced (8.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: VNRX insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.5%.


Top Shareholders

Company Information

VolitionRx Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: VolitionRx Limited
  • Ticker: VNRX
  • Exchange: AMEX
  • Founded:
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$143.764m
  • Shares outstanding: 46.23m
  • Website: https://www.volition.com

Number of Employees


Location

  • VolitionRx Limited
  • 13215 Bee Cave Parkway
  • Suite 125
  • Austin
  • Texas
  • 78738
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
VNRXAMEX (NYSE MKT LLC)YesCommon StockUSUSDOct 2011

Biography

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. The company develops blood-based Nu.Q i ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/19 06:19
End of Day Share Price2020/09/18 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.